WINTON GROUP Ltd Acquires 43,197 Shares of Edwards Lifesciences Corporation $EW

WINTON GROUP Ltd increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 139.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,078 shares of the medical research company’s stock after buying an additional 43,197 shares during the period. WINTON GROUP Ltd’s holdings in Edwards Lifesciences were worth $5,794,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $28,000. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences during the first quarter worth $26,000. NewSquare Capital LLC increased its holdings in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares during the last quarter. SouthState Corp acquired a new position in Edwards Lifesciences in the first quarter valued at about $27,000. Finally, Atlantic Union Bankshares Corp acquired a new position in Edwards Lifesciences in the second quarter valued at about $40,000. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EW. Truist Financial set a $92.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday. Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, November 3rd. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $92.91.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. This represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $86.26 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The firm has a market cap of $50.05 billion, a price-to-earnings ratio of 37.18, a price-to-earnings-growth ratio of 3.82 and a beta of 0.97. The stock’s 50-day moving average is $80.95 and its 200-day moving average is $78.76. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.